Sequent Scientific informs about company updates

22 Sep 2018 Evaluate

Sequent Scientific has informed that the Company has entered into a Business transfer agreement with Solara Active Pharma Sciences Limited to acquire the EU-GMP API facility at Mahad (Mahad facility). The total consideration for the unit would be Rs 46.4 crores on an Enterprise Valuation basis. The acquired Mahad facility compliments the current manufacturing at Vizag (USFDA approved) and Tarapur (Intermediates).

The above information is a part of company’s filings submitted to BSE.

Viyash Scientific Share Price

201.50 7.40 (3.81%)
22-Jan-2026 15:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1634.40
Dr. Reddys Lab 1217.15
Cipla 1374.60
Zydus Lifesciences 883.85
Lupin 2165.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×